Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344)

Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344)

Ribupatide (HRS9531) · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Ribupatide (HRS9531)
Population
t2d
Official title
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase
3
Registry status
completed · 2024-10 → 2026-07
Participants
884
Duration
36 weeks
Registry
NCT06649344

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
4 mg vs semaglutide 1 mg: HbA1c -2.29t2d china36———−2.8——————press release
2 mg vs semaglutide 1 mg: HbA1c -2.29t2d china36———−2.3——————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (2)
  • 4 mg · hba1c · press release
    the mean HbA1c reductions in the ribupatide injection 4 mg and 2 mg groups reached 2.78% and 2.34%, respectively, compared to 2.29% in the semaglutide injection 1 mg group
  • 2 mg · hba1c · press release
    the mean HbA1c reductions in the ribupatide injection 4 mg and 2 mg groups reached 2.78% and 2.34%, respectively, compared to 2.29% in the semaglutide injection 1 mg group

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ribupatide-t2d-phase-3-after-metformin-sglt2i/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.